What is step therapy and why do insurers use it?

Step therapy (also called fail-first protocols) is a utilization management practice where insurers require patients to try and fail lower-cost or preferred treatments before covering a more expensive or non-preferred treatment. Insurers use step therapy to control costs and ensure evidence-based sequencing of care. Common step therapy examples include requiring a trial of generic metformin before covering a branded GLP-1 drug, or requiring a trial of a first-line NSAID before covering a biologic for rheumatoid arthritis. Step therapy is not inherently inappropriate, but the requirement may not fit every patient's clinical situation.

What are the standard criteria for a step therapy exception?

Exception criteria vary by insurer, plan, and state law, but common grounds include: (1) documented prior failure, intolerance, or contraindication to each required step-therapy drug; (2) clinical guidelines or published evidence supporting the requested drug as first-line for this specific patient's diagnosis; (3) a condition or comorbidity that makes the step-therapy drug medically inappropriate (e.g., a contraindicated allergy, organ impairment affecting metabolism, or interaction with a necessary concurrent medication); (4) the patient already successfully started the requested drug and switching would cause clinical harm. Each ground requires specific documentation from the prescribing provider.

Do state step therapy override laws apply to my plan?

Many states have enacted step therapy override or exception laws, but coverage and scope vary significantly by state. These laws typically apply to state-regulated fully insured health plans. They generally do not apply to self-insured (self-funded) ERISA employer plans, which are governed by federal law and not subject to most state insurance mandates. If your employer plan is self-insured (ask your HR department or check your plan documents), your appeal rights come from ERISA and the plan's own terms rather than state step therapy statutes. Check your state insurance department's website to determine whether your state has a step therapy law and which plans it covers.

How does Medicare Part D handle step therapy exceptions?

Medicare Part D plans may use step therapy for certain drugs, and beneficiaries have the right to request a coverage determination or formulary exception when the step-therapy drug is contraindicated, ineffective, or not in the patient's best interest. The Part D exception process requires a statement of medical necessity from the prescribing physician. Expedited exception requests must be decided within 24 hours when applying the standard timeframe would seriously jeopardize the enrollee's health. CMS Part D regulations at 42 CFR Part 423 govern the exception and appeal process.

What documents do I need to appeal a step therapy denial?

Gather: the denial letter with the specific step-therapy requirement and denial reason; the prescribing provider's clinical notes documenting the patient's diagnosis, prior treatment history (including dates, doses, and outcomes of required step-therapy drugs), and reason the step-therapy drug is inappropriate; a Letter of Medical Necessity explaining why the exception criteria are met; any relevant lab results, imaging, or allergy records; and published clinical guidelines or literature supporting the requested drug. Your appeal letter should address each required step-therapy drug individually — documenting failure, intolerance, or contraindication for each one.

Can I request a peer-to-peer review for a step therapy denial?

Yes. A peer-to-peer review between your prescribing physician and the insurer's medical reviewer is often the fastest way to resolve a step therapy denial. The physician can explain why the patient's clinical situation warrants an exception — for example, a specific contraindication, a documented adverse reaction to the preferred drug, or clinical guidelines that support the requested treatment for this patient's specific subtype of the diagnosis. Request the peer-to-peer immediately after receiving the denial, before the window closes (typically 2–5 business days).

What happens if my step therapy appeal is denied internally?

After exhausting internal appeals for an ACA-regulated or ERISA plan, you generally have the right to independent external review. The external reviewer evaluates whether the step therapy requirement and its application were consistent with clinical evidence and plan terms. External reviewer decisions are binding on the insurer. For Part D, the escalation path is: plan redetermination → Independent Review Entity (IRE) → ALJ hearing → Medicare Appeals Council → federal district court. For state-regulated plans with step therapy laws, your state insurance commissioner may also have a complaint or appeal process.

Is step therapy different for weight-loss medications like GLP-1 drugs?

Step therapy for GLP-1 medications (semaglutide, tirzepatide) commonly requires prior failure of a lower-cost weight-loss intervention — such as documented dietary counseling, behavioral therapy, or a prior anti-obesity medication. Exception criteria often include a BMI above the plan's threshold, a qualifying comorbidity (type 2 diabetes, hypertension, sleep apnea), and documentation that prior interventions were attempted and insufficient. Coverage rules for weight-loss drugs vary significantly by plan and state; Medicare Part D still generally excludes weight-loss drugs from standard coverage as of 2026. See our dedicated guide on appealing step therapy for weight-loss medications for drug-specific strategies.

How to Appeal a Step Therapy Denial

By Medical Claims Advocacy Team•15 min read•Published August 2026

How do you appeal a step therapy denial? Document that you meet one or more exception criteria: prior failure of the required drug, intolerance, contraindication, or a clinical reason the preferred drug is inappropriate for your specific diagnosis. Submit a formal internal appeal with your provider's clinical notes, a Letter of Medical Necessity, and evidence addressing each step the insurer required. Many states have step therapy override laws for state-regulated plans, but self-insured ERISA employer plans are generally governed by federal law. If the internal appeal fails, request independent external review.

What Step Therapy Is — and Why It Gets Denied

Key Takeaway: Step therapy requires patients to try and fail preferred (usually lower-cost) treatments before an insurer will cover a more expensive option. A step therapy denial means the insurer says you haven't completed the required steps yet — or that the documentation submitted doesn't prove you did.

Step therapy is also called a “fail-first” policy. When your doctor prescribes a medication or treatment, the insurer may require that you first try one or more alternatives — typically cheaper generics, older drug classes, or behavioral interventions — and document that they were ineffective, caused intolerable side effects, or are clinically contraindicated for your condition.

A step therapy denial can be issued:

Before the first prescription is filled — the PA request for the requested drug is denied because the required steps haven't been completed or aren't documented.
After a formulary exception request — you're requesting a non-preferred drug and the insurer says the preferred drug hasn't been adequately tried.
Mid-treatment — a plan change or formulary update moves your current drug to a tier that requires step therapy for new starts.

The key distinction between a step therapy denial and a general prior authorization denial is that step therapy denials have a specific, known exception pathway. If you meet any of the standard exception criteria and document them properly, the path to overturning the denial is well-defined.

Step Therapy Exception Criteria: What Qualifies

Key Takeaway: Exception criteria are the conditions under which an insurer must waive the step therapy requirement. Common grounds include prior failure of the preferred drug, intolerance or adverse effects, a documented contraindication, or clinical guidelines specifically supporting the requested treatment for this patient. Each ground requires different documentation.

Exception criteria vary by insurer and plan, but the following categories appear across most commercial plan policies and are codified in many state step therapy laws:

Exception Ground	What to Document	Common Evidence
Prior failure of the step drug	Dates, doses, and duration of prior trial; documented inadequate response	Pharmacy records, prescriber notes with outcome documentation
Intolerance or adverse effect	Specific adverse reaction, date it occurred, and why re-challenge is inappropriate	Clinical notes documenting the reaction; allergy/intolerance records
Contraindication	Why the preferred drug is contraindicated by the patient's diagnosis, comorbidity, or concurrent medication	FDA labeling contraindication language; clinical notes; drug interaction data
Clinical guidelines / disease subtype	Published guideline specifically recommending the requested drug as first-line for this patient's subtype	National society guideline citation; peer-reviewed literature; LMN citing guideline
Patient already on drug with clinical stability	Documentation that switching to the step-therapy drug would destabilize a condition already well-managed	Prescriber letter explaining risk of transition; clinical notes showing stable response

When the step therapy requirement involves multiple drugs (e.g., try Drug A then Drug B before Drug C), your appeal must address each step individually. A single documented failure or contraindication to one step drug does not automatically satisfy the requirement for all steps — unless your insurer's policy states otherwise.

State Step Therapy Override Laws: What They Cover — and What They Don't

Key Takeaway: Many states have enacted step therapy exception or override laws, but they apply only to state-regulated fully insured health plans. Self-insured ERISA employer plans — covering a large portion of privately insured Americans — are generally exempt from state insurance mandates including step therapy laws.

As of 2026, a significant number of states have passed step therapy exception legislation requiring insurers to offer exception processes with specific criteria and timelines. These laws vary by state in scope — some require exception decisions within 72 hours; others specify covered diagnoses; some create cause-of-action rights if an insurer ignores an exception. Check your state insurance department's website to determine whether such a law applies in your state.

Critical distinction — ERISA preemption: If your health insurance is through a private employer and the plan is self-insured (the employer pays claims directly rather than paying premiums to an insurance carrier), your plan is an ERISA plan. ERISA preempts most state insurance laws for self-insured plans, meaning state step therapy override laws typically do not apply. Your rights come from ERISA §503 and your plan's own terms. Ask your HR department or benefits administrator whether your plan is fully insured or self-insured.

For ACA marketplace (individual and small-group) plans, state insurance laws generally do apply. These plans are fully insured and regulated by your state's insurance commissioner, so any state step therapy law in your state covers these plans.

Medicare Part D Step Therapy Exception Process

Key Takeaway: Medicare Part D plans that use step therapy must provide a coverage determination exception process. Enrollees can request a formulary exception or coverage determination when a step-therapy drug is contraindicated, ineffective, or otherwise inappropriate. Expedited decisions must be issued within 24 hours for urgent requests.

Under Medicare Part D appeals guidance at Medicare.gov, beneficiaries have the right to request a coverage determination when a drug on their plan's formulary is subject to step therapy requirements. A formulary exception — specifically an “exception to utilization management” — requires a supporting statement from the prescribing physician explaining why the step-therapy drug is not appropriate for this patient.

The Part D exception and appeal escalation path is:

Coverage determination / formulary exception request — submitted to the plan; standard 72-hour decision; expedited 24 hours
Redetermination by the plan if the initial request is denied
Independent Review Entity (IRE) reconsideration — an independent organization contracted by CMS
ALJ hearing — if the amount in dispute meets the threshold (adjusted annually)
Medicare Appeals Council review
Federal district court

For weight-loss medications that may be subject to step therapy under commercial plans, see our guide on how to bypass step therapy for weight-loss medications, which covers GLP-1 specific exception strategies.

Weak vs. Strong Step Therapy Appeal Language

Key Takeaway: A strong step therapy appeal names the specific exception criterion being claimed, cites the exact drug(s) already tried, documents the outcome for each, and attaches the clinical evidence. Weak appeals that argue the treatment is “necessary” without addressing the step therapy criterion are routinely denied.

❌ Weak Appeal Language	✅ Strong Appeal Language
“My doctor prescribed this medication and believes it is the right treatment for me.”	“I am requesting a step therapy exception under the ‘prior failure’ criterion. The patient completed a trial of [Drug A] from [date] to [date] at [dose] as required. Clinical notes from [date], attached as Exhibit A, document [specific inadequate response — e.g., HbA1c remained above 8.5% despite maximum tolerated dose]. The patient was unable to trial [Drug B] due to a documented contraindication — [Drug B] is contraindicated with the patient's concurrent [medication/condition] per FDA labeling (Section 4, attached).”
“The preferred drug doesn't work for everyone and I need the non-preferred one.”	“The patient has a documented hypersensitivity reaction to [Drug A], the required first-step agent, as recorded in allergy documentation dated [date] (Exhibit B). Re-challenge is not clinically appropriate. The [National Society] guidelines (2025, Section 3.4, Exhibit C) designate [requested drug] as first-line therapy for patients with [specific diagnosis subtype] who cannot tolerate [Drug A]. This patient meets the diagnostic criteria for that subtype per pathology report dated [date].”
“We tried the step therapy drugs already. Please approve the medication.”	“Per the step therapy exception criteria in [Insurer] Medical Policy #ST-2026-04, this appeal demonstrates: (1) Failure of [Drug A] — trial dates, dose, outcome per Exhibit A; (2) Intolerance of [Drug B] — documented adverse event per Exhibit B; (3) [Drug C, the requested drug] is supported by [guideline citation] as the appropriate next-line agent for this clinical presentation. I request a written determination within [applicable state or federal deadline].”

Generate Your Step Therapy Exception Appeal

AppealFlow builds a formal step therapy exception appeal citing your specific exception ground, clinical evidence, and applicable law — ready to submit to your insurer.

Step Therapy Appeal Generator

After the Internal Step Therapy Appeal: External Review

Key Takeaway: If the internal appeal is denied, ACA-regulated and most ERISA plans must offer external independent review for medical necessity decisions — including step therapy medical judgment calls. The external reviewer's decision is binding on the insurer.

External independent review is available after internal appeals are exhausted (or the plan fails to decide within required timeframes). For step therapy denials, whether the denial qualifies as a “medical necessity” denial — which is eligible for external review — or a “plan exclusion” (which may not be) depends on the basis of the denial. Most step therapy denials are clinical judgment decisions and are eligible for external review.

For GLP-1 and weight-loss drug step therapy specifically — where plan exclusions of the drug class itself (not just step therapy) are common — a contractual exclusion may not be reviewable through external review. In those cases, the strategy shifts to formulary exception or a different appeal path. See our GLP-1 denial appeal generator for a drug-category-specific approach.

Frequently Asked Questions

Common questions about step therapy denials, exception criteria, state laws, Medicare Part D exceptions, and how to document prior failure or contraindication.

Generate Your Step Therapy Appeal Letter

AppealFlow drafts formal step therapy exception appeal letters — citing your exception ground, clinical documentation, and applicable ERISA or ACA appeal rights. Edit live, download as PDF or Word. No account required.

Step Therapy Appeal Generator GLP-1 Denial Appeal

100% Free
No Signup
PDF & Word Export

Disclaimer: This article is for educational purposes only and does not constitute medical, legal, or financial advice. AppealFlow.net is not a healthcare provider, insurance broker, or law firm. Step therapy laws vary by state and do not apply to self-insured ERISA employer plans — confirm your plan type before relying on state law. Medicare Part D step therapy exception procedures are governed by CMS at Medicare.gov. See our full disclaimer.